Affiliation:
1. Department of Microbiology, MGMCRI, Pondicherry, India
2. Department of Microbiology, MGMCRI, Pondicherry, India.
Abstract
Aim:The aim of our study is to correlate drug resistance patterns with Lipase production in clinical isolates of Klebsiella pneumoniae.
Materials and Methods:Atotal of 150 clinical isolates of Klebsiella pneumoniae from various clinical samples collected during the period from
July 2020 to December 2020 was included in this study. Lipase production was detected by tween 80 agar and an antibiotic susceptibility test has
been performed by Kirby-Bauer disk diffusion method as per CLSI guidelines [10]. Extended Spectrum Beta-lactamase (ESBL) producers were
detected by combined disc diffusion method and Carbapenemase production was detected by using the E-test strip method.
Results and Discussion: Out of 150 consecutive non-duplicate isolates of Klebsiella pneumoniae, 74 isolates from Exudate, 7 from Blood, and 69
were from urine. Among 150 isolates, 85(56.6%) isolates produced Lipase production, 43(57.3%) were ESBL producers and 20(32.25%) isolates
were positive for Carbapenemase production.
Conclusion: Showing virulence in clinical isolates of Klebsiella pneumoniae, and the antibiotic susceptibility pattern with lipase production in
Klebsiella pneumoniae were noticed. If the virulence is increased in Klebsiella pneumoniae, a drug-resistant pattern also shows more resistance in
number. And nally, to correlate the ESBL and Carbapenemase producer with lipase production, in that also the ESBL and Carbapenemase
producer shows more number with lipase production. And also noted, when compared with outpatients, inpatients show more lipase production.
And hence ampicillin is an intrinsic resistance to Klebsiella pneumoniae. In this study, to correlate the drug-resistant pattern, ESBL, and
carbapenemase producer with lipase production in clinical isolates of Klebsiella pneumoniae.
Reference30 articles.
1. Ananth Narayanan R, Panikkar CKJ. Textbook of Microbiology. 7th Edition of Microbiology. Blackswan. 2006.
2. Levy SB. Impacting on the problem of Antibiotic Resistance. Journal of Antimicrobial Chemotherapy,2002;49(1):25-30.
3. Center for Disease Control and Prevention. Guidance for control of infections with Carbapenemase-resistant of Carbapenemase producing Enterobacteriaceae in acute care facilities. MMWR Morbidity and mortality weekly report. 2009;58: 256-260.
4. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. Controlling the spread of carbapenemase-producing Gram negatives: Therapeutic Approach and Infection control. Clin Microbial Infect, 2010;16: 102-111.
5. Cohen MJ, Block C, Levin PD, Schwartz C, Gross I, Weiss Y, Moses AE, Benson S, Institutional control measures to curtail the epidemic spread of Carbapenemase-resistant Klebsiella pneumoniae: a 4- year perspective. Infect Control Hosp Epidemiol. 2011;32: 673-678.